Article
作者: Blanc, Pierluigi ; Niro, Grazia Anna ; Zignego, Anna Linda ; Foschi, Francesco Giuseppe ; Madonia, Salvatore ; Ciancio, Alessia ; Tosti, Maria Elena ; Ieluzzi, Donatella ; Rosato, Valerio ; Ferrarese, Alberto ; Puoti, Massimo ; Rianda, Alessia ; Gentile, Ivan ; Stanzione, Maria ; Barbaro, Francesco ; Kondili, Loreta A ; Gaeta, Giovanni Battista ; Russo, Francesco Paolo ; Brancaccio, Giuseppina ; Morsica, Giulia ; Pellicelli, Adriano ; Laccabue, Diletta ; Cacciola, Irene ; Coco, Barbara ; Claar, Ernesto ; Massari, Marco ; Marrone, Aldo ; Surace, Lorenzo ; Coppola, Roberta ; Toniutto, Pierluigi ; Santantonio, Teresa Antonia ; Soria, Alessandro ; Messina, Vincenzo ; Ponziani, Francesca Romana ; Degasperi, Elisabetta ; Biliotti, Elisa ; Raimondo, Giovanni ; Fagiuoli, Stefano ; Rocco, Alba ; Coppola, Nicola ; Bassetti, Matteo ; Milella, Michele ; Maida, Ivana ; Barchiesi, Francesco ; Longobardi, Francesco ; Di Marco, Vito ; Quaranta, Maria Giovanna ; Viganò, Mauro ; Brunetto, Maurizia Rossana ; Rosselli Del Turco, Elena ; Cossiga, Valentina ; De Santis, Adriano ; Chemello, Liliana ; Chessa, Luchino ; Ciarallo, Marianna ; Craxi, Antonio ; Federico, Alessandro ; Cerrito, Lucia ; Baiocchi, Leonardo ; Morisco, Filomena
BACKGROUND AND AIMSWe aimed to characterize the epidemiologic and comorbidities profiles of patients with chronic Hepatitis D (CHD) followed in clinical practice in Italy and explored their interferon (IFN) eligibility.METHODSThis was a cross-sectional study of the PITER cohort consisting of consecutive HBsAg-positive patients from 59 centers over the period 2019-2023. Multivariable analysis was performed by logistic regression model.RESULTSOf 5492 HBsAg-positive enrolled patients, 4152 (75.6%) were screened for HDV, 422 (10.2%) were anti-HDV positive. Compared with HBsAg mono-infected, anti-HDV positive patients were more often younger, non-Italians, with a history of drug use, had elevated alanine transaminase (ALT), cirrhosis, or hepatocellular carcinoma (HCC). Compared with Italians, anti-HDV positive non-Italians were younger (42.2% age ≤ 40 years vs. 2.1%; P < 0.001), more often females (males 43.0% vs. 68.6%; P < 0.001) with less frequent cirrhosis and HCC. HDV-RNA was detected in 63.2% of anti-HDV-positive patients, who were more likely to have elevated ALT, cirrhosis, and HCC. Extrahepatic comorbidities were present in 47.4% of anti-HDV positive patients and could affect the eligibility of IFN-containing therapies in at least 53.0% of patients in care.CONCLUSIONSCHD affects young, foreign-born patients and older Italians, of whom two-thirds had cirrhosis or HCC. Comorbidities were frequent in both Italians and non-Italians and impacted eligibility for IFN.